TTR and cardiac amyloidosis: Furthermore, new and even more effective therapies are currently under evaluation and may become available in the near future for therapy escalation (HELIOS-B: A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149; ION-682884 in Patients With TTR Amyloid Cardiomyopathy; NCT04843020).